Skip to main content

Oncology

Featured

Tobey MacDonald, MD, Children's Healthcare Atlanta
Videos
11/19/2026
Tobey MacDonald, MD, discusses his approach to tovorafenib dose adjustments and supportive care, reflecting on how FIREFLY-1 findings could inform management of asymptomatic laboratory abnormalities.
Tobey MacDonald, MD, discusses his approach to tovorafenib dose adjustments and supportive care, reflecting on how FIREFLY-1 findings could inform management of asymptomatic laboratory abnormalities.
Tobey MacDonald, MD, discusses...
11/19/2026
Oncology
News
11/19/2026
Stephanie Holland
Results from the phase 3 REGAL trial demonstrated that galinpepimut-S maintenance significantly improved overall survival compared with best available treatment in acute myeloid leukemia following second or later remission, supporting the...
Results from the phase 3 REGAL trial demonstrated that galinpepimut-S maintenance significantly improved overall survival compared with best available treatment in acute myeloid leukemia following second or later remission, supporting the...
Results from the phase 3 REGAL...
11/19/2026
Oncology
Quiz
11/19/2026
Test your knowledge of the FDA's accelerated approval of neladalkib for previously treated ALK-positive locally advanced or metastatic non-small cell lung cancer, including patient eligibility, prior treatment requirements, and clinical...
Test your knowledge of the FDA's accelerated approval of neladalkib for previously treated ALK-positive locally advanced or metastatic non-small cell lung cancer, including patient eligibility, prior treatment requirements, and clinical...
Test your knowledge of the FDA's...
11/19/2026
Oncology
Kenneth Aldape, MD
Videos
11/18/2026
Kenneth Aldape, MD
Kenneth Aldape, MD, discusses advances in artificial intelligence-assisted tumor diagnosis, highlighting DNA methylation profiling, histopathology-based prediction of epigenomic signatures, and improved pathologist performance with artificial...
Kenneth Aldape, MD, discusses advances in artificial intelligence-assisted tumor diagnosis, highlighting DNA methylation profiling, histopathology-based prediction of epigenomic signatures, and improved pathologist performance with artificial...
Kenneth Aldape, MD, discusses...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a prospective study...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a deep learning...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the...
11/18/2026
Oncology
FDA Alerts
11/18/2026
Emily Estrada
The FDA has issued a Complete Response Letter for ivonescimab plus platinum-based chemotherapy in previously treated EGFR-mutated advanced non-small cell lung cancer, determining that the significant progression-free survival benefit observed...
The FDA has issued a Complete Response Letter for ivonescimab plus platinum-based chemotherapy in previously treated EGFR-mutated advanced non-small cell lung cancer, determining that the significant progression-free survival benefit observed...
The FDA has issued a Complete...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Results from a clinical...
11/18/2026
Oncology
News
11/17/2026
Stephanie Holland
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Updated results from the phase 2...
11/17/2026
Oncology

Videos

Tobey MacDonald, MD, Children's Healthcare Atlanta
Videos
11/19/2026
Tobey MacDonald, MD, discusses his approach to tovorafenib dose adjustments and supportive care, reflecting on how FIREFLY-1 findings could inform management of asymptomatic laboratory abnormalities.
Tobey MacDonald, MD, discusses his approach to tovorafenib dose adjustments and supportive care, reflecting on how FIREFLY-1 findings could inform management of asymptomatic laboratory abnormalities.
Tobey MacDonald, MD, discusses...
11/19/2026
Oncology
Kenneth Aldape, MD
Videos
11/18/2026
Kenneth Aldape, MD
Kenneth Aldape, MD, discusses advances in artificial intelligence-assisted tumor diagnosis, highlighting DNA methylation profiling, histopathology-based prediction of epigenomic signatures, and improved pathologist performance with artificial...
Kenneth Aldape, MD, discusses advances in artificial intelligence-assisted tumor diagnosis, highlighting DNA methylation profiling, histopathology-based prediction of epigenomic signatures, and improved pathologist performance with artificial...
Kenneth Aldape, MD, discusses...
11/18/2026
Oncology
Marcelo Negrao, MD
Videos
11/17/2026
Marcelo Negrao, MD
Marcelo Negrao, MD, discusses updated findings from the LOXO-RAS-20001 and SUNRAY-01 trials, presented at the 2026 European Society for Medical Oncology (ESMO) Congress. The integrated analysis evaluated olomorasib, a KRAS G12C inhibitor, in...
Marcelo Negrao, MD, discusses updated findings from the LOXO-RAS-20001 and SUNRAY-01 trials, presented at the 2026 European Society for Medical Oncology (ESMO) Congress. The integrated analysis evaluated olomorasib, a KRAS G12C inhibitor, in...
Marcelo Negrao, MD, discusses...
11/17/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
Beth Faiman, CNP, PhD
12/15/26: Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasms | Multiple Myeloma
12/15/26: Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasms | Multiple Myeloma
12/15/26: Chronic Lymphocytic...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
John Mascarenhas, MD
12/14/26: Leukemia | Lymphoma | Multiple Myeloma | Transplant
12/14/26: Leukemia | Lymphoma | Multiple Myeloma | Transplant
12/14/26: Leukemia | Lymphoma |...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
C. Ola Landgren, MD, PhD; Naval G. Daver
12/13/26: Hematologic Malignancies | Multiple Myeloma | CAR T and T-Cell Engagers
12/13/26: Hematologic Malignancies | Multiple Myeloma | CAR T and T-Cell Engagers
12/13/26: Hematologic...
11/16/2026
Oncology

Insights From the ASCO Annual Meeting

News
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

Marcelo Negrao, MD
Videos
11/17/2026
Marcelo Negrao, MD
Marcelo Negrao, MD, discusses updated findings from the LOXO-RAS-20001 and SUNRAY-01 trials, presented at the 2026 European Society for Medical Oncology (ESMO) Congress. The integrated analysis evaluated olomorasib, a KRAS G12C inhibitor, in...
Marcelo Negrao, MD, discusses updated findings from the LOXO-RAS-20001 and SUNRAY-01 trials, presented at the 2026 European Society for Medical Oncology (ESMO) Congress. The integrated analysis evaluated olomorasib, a KRAS G12C inhibitor, in...
Marcelo Negrao, MD, discusses...
11/17/2026
Oncology
Shannon Westin, MD
Videos
11/13/2026
Shannon Westin, MD
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The...
11/13/2026
Oncology
Eleftherios Mamounas, MD, MPH, FACS
Videos
11/13/2026
Eleftherios Mamounas, MD
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD,...
11/13/2026
Oncology
Nikhil Khushalani, MD
Videos
11/12/2026
Nikhil Khushalani, MD
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD,...
11/12/2026
Oncology
Jacob Sands, MD
Videos
11/12/2026
Jacob Sands, MD
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the...
11/12/2026
Oncology
Sara Hurvitz, MD
Videos
11/11/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses...
11/11/2026
Oncology
Benjamin Garmezy, MD
Videos
11/11/2026
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses...
11/11/2026
Oncology
Nilofer Azad, MD
Videos
11/11/2026
Nilofer Azad, MD
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses...
11/11/2026
Oncology
Matteo S. Carlino, MD
Videos
11/11/2026
Matteo Carlino, MD
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses...
11/11/2026
Oncology
Jaafar Bennouna, MD, PhD
Videos
11/10/2026
Jaafar Bennouna, MD, PhD
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD,...
11/10/2026
Oncology

Live Meetings